A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...

Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) and granted Priority Review designation for the investigational compound ...

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

Enantiomers, or molecule pairs that are mirror images of each other, make up more than half of FDA-approved drugs in use ...

Through the trial, which began in May, the team aims to confirm the safety and efficacy of the treatment, with hopes of ...

THE Food and Drug Administration (FDA) said it suspended the new registration and assessment fees for medical products after ...